Swiss pharma giant Roche (ROG: SIX) today revealed some important changes to its corporate executive committee.
The company said that Teresa Graham, currently head of global product strategy for Roche Pharmaceuticals, has been appointed chief executive of Roche Pharmaceuticals based in Basel, Switzerland effective March 2023 and will become a member of the corporate executive committee.
At the same time, Levi Garraway, chief medical officer and executive vice president, global product development, based in South San Francisco, will become a member of the enlarged corporate executive committee. Both will report to the Roche Group CEO, Thomas Schinecker, when he takes over the role in March 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze